The novel benzopyran class of selective cyclooxygenase-2 inhibitors-part I: The first clinical candidate

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 23, 2010, Pages 7155-7158

  Wang, Jane L ^a   Carter, Jeffery ^a   Kiefer, James R ^a   Kurumbail, Ravi G ^a   Pawlitz, Jennifer L ^a   Brown, David ^a   Hartmann, Susan J ^a   Graneto, Matthew J ^a   Seibert, Karen ^a   Talley, John J ^a  

^a PFIZER INC   (United States)

Author keywords

Benzopyran; Clinical candidate; COX 2 inhibitor; Cyclooxygenase; Half life; Plasma protein bound; X ray crystal structure

Indexed keywords

2 TRIFLUOROMETHYL 2H BENZOPYRAN 3 CARBOXYLIC ACID DERIVATIVE; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; BENZOPYRAN DERIVATIVE; CELECOXIB; CHROMENE DERIVATIVE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; SD 8381; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; CRYSTAL STRUCTURE; DOG; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; IC 50; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

BENZOPYRANS; BLOOD PROTEINS; CARBOXYLIC ACIDS; CYCLOOXYGENASE 2 INHIBITORS; HALF-LIFE; HUMANS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78149260251     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.07.053     Document Type: Article

References (29)

1. K.D. Rainsford, and K. D V. Rainsford, Side-effects of Anti-inflammatory Drugs Vol. 2 1985 MTP Press Norwell, Massachusetts 343 362
2. M.C. Allison, A.G. Howatson, C.J. Torrance, F.D. Lee, and R.I.G. Russel N. Eng. J. Med. 327 1992 749
3. R.C. Haynes Jr. A.G. Gilman, T.W. Rall, A.S. Nies, P. Taylor, The Pharmacological Basis of Therapeutics 8th ed. 1993 McGraw-Hill New York 1442 1452
4. J.R. Vane Nat. New Biol. 231 1971 232
5. J.J. Talley Prog. Med. Chem. 36 1999 201
6. J.L. Masferrer, B.S. Zweifel, P.T. Manning, S.D. Hauser, K.M. Leahy, W.G. Smith, P.C. Isakson, and K. Seibert Proc. Natl. Acad. Sci. U.S.A. 91 1994 3228
7. K. Seibert, Y. Zhang, K. Leahy, S. Hauser, J.L. Masferrer, W. Perkins, L. Lee, and P.C. Isakson Proc. Natl. Acad. Sci. U.S.A. 91 1994 12013
8. P. Peptiboon, and D. Riendea Annu. Rep. Med. Chem. 32 1997 211
9. J.R. Vane, Y.S. Bakhle, and R.M. Botting Annu. Rev. Pharmacol. Toxicol. 38 1998 97
10. L.S. Simon, F.L. Lanza, P.E. Lipsky, R.C. Hubbard, S. Talwalker, B.D. Schwartz, P.C. Isakson, and G.S. Geis Arthritis Rheum. 41 1998 1591
11. L.J. Crofford, J.C. Oates, W.J. McCune, S. Gupta, M.J. Kaplan, F. Catella-Lawson, J.D. Morrow, K.T. McDonagh, and A.H. Schmaier Arthritis Rheum. 43 2000 1891
12. Z.A. Radi, and N.K. Khan Exp. Toxicol. Pathol. 58 2006 163
13. R.F. Jacoby, K. Seibert, C.E. Cole, G. Kelloff, and R.A. Lubet Cancer Res. 60 2000 5040
14. S.J. Baek, and T.E. Eling Prog. Lipid Res. 45 2006 1
15. The Pfizer Institutional Animal Care and Use Committee reviewed and approved the animal use in these studies. The animal care and use program is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International.
16. Y. Zhang, A. Shaffer, J. Portanova, K. Seibert, and P.C. Isakson J. Pharmacol. Exp. Ther. 283 1997 1069
17. J.P. Portanova, Y. Zhang, G.D. Anderson, S.D. Hauser, J.L. Masferrer, K. Seibert, S.A. Gregory, and P.C. Isakson J. Exp. Med. 184 1996 883
18. J. Gierse, M. Nickols, K. Leahy, J. Warner, Y. Zhang, L. Cortes-Burgos, J. Carter, K. Seibert, and J. Masferrer Eur. J. Pharmacol. 588 2008 93
19. Aston, K. W.; Brown, D. L.; Carter, J. S.; Deprow, A. M.; Fletcher, T. R.; Hallinan, E. A.; Hamper, B. C.; Huff, R. M.; Kiefer, J. R., Jr.; Koszyk, F.; Kramer, S. W.; Liao, S.; Limburg, D.; Springer, J. R.; Tsymbalov, S.; Wang, L. J.; Xing, L.; Yu, Y. WO 04087687 A1, 2004.
20. Carter, J.; Obukowicz, M.; Talley, J.; Brown, D.; Graneto, M.; Bertenshaw, S.; Rogier, D.; Nagarajan, S.; Hanau, C.; Hartmann, S.; Ludwig, C.; Metz, S. US006034256A, 2000.
21. Carter, J.; Obukowicz, M.; Devadas, B.; Talley, J.; Brown, D.; Graneto, M.; Bertenshaw, S.; Rogier, D.; Nagarajan, S.; Hanau, C.; Hartmann, S.; Ludwig, C.; Metz, S.; Korte, D. US006077850A, 2000.
22. 50 values with subtle changes in assay protocol.
23. R.G. Kurumbail, A.M. Stevens, J.K. Gierse, J.J. McDonald, R.A. Stegeman, J.Y. Pak, D. Gildehaus, J.M. Miyashiro, T.D. Penning, K. Seibert, P.C. Isakson, and W.C. Stallings Nature 384 1996 644
24. J.K. Gierse, J.J. McDonald, S.D. Hauser, S.H. Rangwala, C.M. Koboldt, and K. Seibert J. Biol. Chem. 271 1996 15810
25. D. Picot, P.J. Loll, and R.M. Garavito Nature 367 1994 243
26. J.A. Mancini, D. Riendeau, J.P. Falgueyret, P.J. Vickers, and G.P. O'Neill J. Biol. Chem. 270 1995 29372
27. X-ray structure coordinates for all complexes have been deposited into the Protein Data Bank with accession codes 3LN1 (celecoxib) and 3LN0 (5c-(S)). Data for the crystal structures described herein were collected at IMCA-CAT (17-ID) beamline at the Advanced Photon Source and was supported by the companies of the Industrial Macromolecular Crystallography Association through a contract with the Center for Advanced Radiation Sources at the University of Chicago.
28. S.W. Rowlinson, J.R. Kiefer, J.J. Prusakiewicz, J.L. Pawlitz, K.R. Kozak, A.S. Kalgutkar, W.C. Stallings, R.G. Kurumbail, and L.J. Marnett J. Biol. Chem. 278 2003 45763
29. J.R. Kiefer, J.L. Pawlitz, K.T. Moreland, R.A. Stegeman, W.F. Hood, J.K. Gierse, A.M. Stevens, D.C. Goodwin, S.W. Rowlinson, L.J. Marnett, W.C. Stallings, and R.G. Kurumbail Nature 405 2000 97